The South San Francisco-based drug developer plans to list on Nasdaq under the ticker "ETRA," offering approximately 21.67 million shares at a price range of $14 to $16 per share. This listing comes amid a resurgence in biotech IPOs, with Electra Therapeutics intending to use the IPO proceeds to fund clinical trials for its lead experimental drug, ipsoprubart, and advance the development of its second candidate, ELA822.